Search research articles
Contact Us
Filters
Showing results (91-100 of 107) with videos related to
Page
of 11
Sort By:
Revue Du Rhumatisme (Ed. Francaise : 1993)
|
December 1, 1993
[Bone metastasis of hepatocellular carcinoma. Apropos of 22 cases]
J F Maillefert, J Tebib, S Aho, et al.
Annales De Biologie Clinique
|
April 9, 2002
[Interpretation of the CA125 kinetics during first line chemotherapy of the ovarian cancer: methodological aspects and characteristic profiles]
J M Riedinger, N Eche, J P Basuyau, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 29, 2013
Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study)
M Ducreux, A Adenis, J-P Pignon, et al.
Journal of Neuro-Oncology
|
July 21, 2019
Long-term survival in patients with recurrent glioblastoma treated with bevacizumab: a multicentric retrospective study
M C Morisse, N Etienne-Selloum, D Bello-Roufai, et al.
Cell Death and Differentiation
|
November 13, 2010
Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level
A Morizot, D Mérino, N Lalaoui, et al.
Respiratory Medicine and Research
|
June 9, 2020
Predictive factors for the participation of general practitioners in lung cancer screening by low-dose CT scan in the Somme department in northern France
O Leleu, G Vincent, M Auquier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 10, 2008
Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study
B Chauffert, F Mornex, F Bonnetain, et al.
Clinical and Experimental Immunology
|
October 25, 2007
Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes
S Audia, A Nicolas, D Cathelin, et al.
Leukemia
|
February 24, 2001
Phase I study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromes
E Solary, L Mannone, D Moreau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 10, 2011
Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab
D Malka, V Boige, N Jacques, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 107) with videos related to
Sort By:
Page
of 11
Revue Du Rhumatisme (Ed. Francaise : 1993)
|
December 1, 1993
[Bone metastasis of hepatocellular carcinoma. Apropos of 22 cases]
J F Maillefert, J Tebib, S Aho, et al.
Annales De Biologie Clinique
|
April 9, 2002
[Interpretation of the CA125 kinetics during first line chemotherapy of the ovarian cancer: methodological aspects and characteristic profiles]
J M Riedinger, N Eche, J P Basuyau, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 29, 2013
Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study)
M Ducreux, A Adenis, J-P Pignon, et al.
Journal of Neuro-Oncology
|
July 21, 2019
Long-term survival in patients with recurrent glioblastoma treated with bevacizumab: a multicentric retrospective study
M C Morisse, N Etienne-Selloum, D Bello-Roufai, et al.
Cell Death and Differentiation
|
November 13, 2010
Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level
A Morizot, D Mérino, N Lalaoui, et al.
Respiratory Medicine and Research
|
June 9, 2020
Predictive factors for the participation of general practitioners in lung cancer screening by low-dose CT scan in the Somme department in northern France
O Leleu, G Vincent, M Auquier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 10, 2008
Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study
B Chauffert, F Mornex, F Bonnetain, et al.
Clinical and Experimental Immunology
|
October 25, 2007
Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes
S Audia, A Nicolas, D Cathelin, et al.
Leukemia
|
February 24, 2001
Phase I study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromes
E Solary, L Mannone, D Moreau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 10, 2011
Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab
D Malka, V Boige, N Jacques, et al.
Page
of 11